{"id":56162,"date":"2023-04-24T22:07:49","date_gmt":"2023-04-24T20:07:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/"},"modified":"2023-04-24T22:07:49","modified_gmt":"2023-04-24T20:07:49","slug":"ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/","title":{"rendered":"Ligand to Report First Quarter 2023 Financial Results on May 4, 2023"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–$LGND<\/a> #earnings<\/a>—Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) <\/b>will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the call will include Ligand\u2019s CEO Todd Davis, President and COO Matt Korenberg, and CFO Tavo Espinoza.<\/p>\n

<\/a><\/p>\n

\nConference Call and Webcast Information<\/b><\/p>\n\n\n\n\n\n\n\n
\n

\nDate:<\/p>\n<\/td>\n

\n

\nThursday, May 4, 2023<\/p>\n<\/td>\n<\/tr>\n

\n

\nTime:<\/p>\n<\/td>\n

\n

\n4:30 p.m. Eastern time (1:30 p.m. Pacific time)<\/p>\n<\/td>\n<\/tr>\n

\n

\nConference Call:<\/p>\n<\/td>\n

\n

\n(888) 350-3452 (U.S. toll-free number)<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n1 (646) 960-0369 (ex-U.S. toll dial-in number)<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nConference ID is 6501694<\/p>\n<\/td>\n<\/tr>\n

\n

\nWebcast:<\/p>\n<\/td>\n

\n

\nLive and replay webcasts of the call are available here<\/a>.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout Ligand Pharmaceuticals Incorporated (\u201cLigand\u201d)<\/b><\/p>\n

\nLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our platform technologies or both. Our business model generates value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding mid to late-stage drug development in return for economic rights and licensing our technology platforms to help partners discover and develop medicines. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to generate our revenue. We have two primary platform technologies that are available for outlicense \u2013 Captisol and Pelican. Our Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. For our Captisol partners, our team supplies the Captisol material needed for their programs. Our Pelican Expression Technology is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. We have established multiple alliances, licenses and other business relationships with the world\u2019s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com<\/a>.<\/p>\n

\nFollow Ligand on Twitter @Ligand_LGND<\/b><\/p>\n

\nWe use Twitter and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our Twitter account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts.<\/p>\n

Contacts<\/b> <\/p>\n

\nLigand Pharmaceuticals Incorporated
\n
Simon Latimer
\n
investors@ligand.com<\/a>
(858) 550-7766
\n
Twitter: @Ligand_LGND<\/p>\n

\nLifeSci Advisors
\n
Bob Yedid
\n
bob@lifesciadvisors.com<\/a>
(516) 428-8577<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–$LGND #earnings—Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56162","6":"format-standard","7":"category-industry"},"yoast_head":"\nLigand to Report First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–$LGND #earnings—Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-24T20:07:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230424005882\/en\/346436\/21\/Ligand-Logo-Registered5.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ligand to Report First Quarter 2023 Financial Results on May 4, 2023\",\"datePublished\":\"2023-04-24T20:07:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/\"},\"wordCount\":454,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230424005882\\\/en\\\/346436\\\/21\\\/Ligand-Logo-Registered5.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/\",\"name\":\"Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230424005882\\\/en\\\/346436\\\/21\\\/Ligand-Logo-Registered5.jpg\",\"datePublished\":\"2023-04-24T20:07:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230424005882\\\/en\\\/346436\\\/21\\\/Ligand-Logo-Registered5.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230424005882\\\/en\\\/346436\\\/21\\\/Ligand-Logo-Registered5.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ligand to Report First Quarter 2023 Financial Results on May 4, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/","og_locale":"en_US","og_type":"article","og_title":"Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–$LGND #earnings—Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-24T20:07:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230424005882\/en\/346436\/21\/Ligand-Logo-Registered5.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ligand to Report First Quarter 2023 Financial Results on May 4, 2023","datePublished":"2023-04-24T20:07:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/"},"wordCount":454,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230424005882\/en\/346436\/21\/Ligand-Logo-Registered5.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/","url":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/","name":"Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230424005882\/en\/346436\/21\/Ligand-Logo-Registered5.jpg","datePublished":"2023-04-24T20:07:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230424005882\/en\/346436\/21\/Ligand-Logo-Registered5.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230424005882\/en\/346436\/21\/Ligand-Logo-Registered5.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ligand-to-report-first-quarter-2023-financial-results-on-may-4-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ligand to Report First Quarter 2023 Financial Results on May 4, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56162"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56162\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}